PhRMA v. HHS
Executive Summary
Vermont requests an en banc rehearing July 23 of D.C. federal appeals court decision that HHS does not have the authority to approve the Vermont Pharmacy Discount Program demonstration project (1"The Pink Sheet" June 11, In Brief)
You may also be interested in...
PhRMA v. HHS
HHS lacks authority to approve Vermont Pharmacy Discount Program demonstration project extending Medicaid drug rebate structure to 70,000 beneficiaries without drug coverage, D.C. federal appeals court rules June 8. The opinion reverses Jan. 18 D.C. federal court decision denying the Pharmaceutical Research & Manufacturers of America's request for a preliminary injunction against the program (1"The Pink Sheet" Jan. 29, p. 7). "Because Congress imposed the rebate requirement in order to reduce the cost of the Medicaid program, and because no Medicaid funds are expended under the Vermont demonstration project and thus no Medicaid savings produced by the required rebates, we conclude that the department lacked the authority to approve the project," the appeals court says
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials